IND regs offer more ways to expand access - and to charge patients for it
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs. A companion reg also gives companies more options for changing patients for experimental products - if they are willing to open their books up to FDA (1"The Pink Sheet," Aug. 17, 2009)
You may also be interested in...
FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs
Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs
ATOM Coalition Seeks Partners To Create New Oncology Markets
The ATOM Coalition is seeking partners in the generics and biosimilars industry to help create new markets for cancer medicines in LLMICs.
Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal
Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.